GlobeNewswire by notified

ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

Share

ObsEva AnnouncesRelationshipwith Syneos Health to Commercialize Linzagolix

-Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of uterine fibroids-

-Financing agreement with JGB Managementto fund the planned launch of linzagolix as well as other development and operational expenses-

-Amendment of Kissei exclusive license and supply agreement -

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland, October 13, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health today announced a strategic relationship with Syneos Health® (Nasdaq:SYHN), the only fully integrated biopharmaceutical solutions organization, to commercialize linzagolix.

Linzagolix has the potential to be a best-in-class GnRH receptor antagonist for the treatment of uterine fibroids due to its efficacy and favorable tolerability profile.1,2,3 If approved, it would be the only GnRH antagonist for uterine fibroids with unique and flexible dosing options, as well as the first to offer a low dose option to address the needs of women who cannot or do not want to take hormones.1,4 Linzagolix is also being evaluated in an ongoing Phase 3 (EDELWEISS 3) study as a potential treatment for endometriosis-associated pain.

Brian O’Callaghan, CEO of ObsEva, commented, “We are thrilled to work with Syneos Health on the commercialization of linzagolix. With a leading women’s health sales force, Syneos Health is uniquely suited to support our goal of offering relief to women suffering from uterine fibroids. While traditional partnering arrangements with large pharma companies were considered, we believe that Syneos Health offers ObsEva the best option to maximize and maintain control, value and optionality for this important product.   This Syneos Health relationship, together with the newly announced financing facility and revised Kissei license terms, provides ObsEva with a strong foundation to execute on its commercialization plans.”

“We are proud to work with ObsEva on the development of a critical treatment that has the potential to change the lives of women suffering from uterine fibroids,” said Michelle Keefe, President, Commercial Solutions at Syneos Health. “We are excited to support ObsEva in their launch utilizing our full-service commercial model including agency, field team, and operations support for linzagolix in both the U.S. and Europe.”

JGB Financing Agreement
ObsEva has also entered into a convertible note financing agreement with certain funds and accounts managed by JGB Management, Inc. which is structured to provide up to $135 million in borrowing capacity, available in nine tranches. The first tranche, for an initial $30 million, was funded at closing and used to retire the existing debt facility with Oxford Finance LLC. Notes issued in connection with each tranche will have a three-year term. All principal and interest will be convertible into ObsEva’s common shares at a price of $3.20 per share.   In connection with each tranche, ObsEva will also issue warrants to purchase its common shares, including a warrant to purchase 1,634,877 common shares that was issued at the initial closing. The warrants will have an exercise price of $3.67 per share and a four year term from the date of issuance. Further information with respect to the debt facility will be provided in a Form 6-K filed by ObsEva with the Securities and Exchange Commission on October 13, 2021. Canaccord Genuity LLC acted as exclusive placement agent and financial advisor to ObsEva.

Kissei License and Supply Agreement
Finally, ObsEva’s exclusive license and supply agreement with Kissei for linzagolix has been amended so that first commercial sales milestones for the EU and the US will now be extended over a 5-year period. In addition, North American royalty payments have been lowered to tiered single digit royalties on net sales plus a supply price for the active pharmaceutical ingredient (API).

About Linzagolix
Linzagolix is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3. Linzagolix has completed clinical trial development for the treatment of heavy menstrual bleeding associated with uterine fibroids and is currently in late-stage clinical development for the treatment of pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.

About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 27,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Cautionary Note Regarding Forward Looking Statements of ObsEva SA
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of and commercialization plans for ObsEva’s product candidates, including linzagolix, expectations regarding regulatory and development milestones, including the potential timing of regulatory submissions to the EMA and FDA and ObsEva’s ability to obtain and maintain regulatory approvals for its product candidates, and the results of interactions with regulatory authorities, and expectations regarding the use of funds from the financing agreement with JGB Management. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, the impact of the ongoing novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with Securities and Exchange Commission (SEC) on March 5, 2021 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602

1. Stewart E, ASRM 2020; Late-breaker abstract P-930
2. Al-Hendy A, NEJM 2021; 384:630-42
3. Schlaff W, NEJM 2020; 382:328-40
4. Bradley L, ASRM 2020; Late-breaker abstract P-931

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fenix Outdoor: Fenix Outdoor International AG Årsredovisning samt Hållbarhetsrapport 202328.3.2024 15:00:00 CET | Pressemelding

Zug 2024-03-28 Press meddelande - Årsredovisning samt Hållbarhetsrapport 2023 Bifogat Års- och Hållbarhetsredovisning för 2023. Årsredovisningen skiljer sig från Q4 pressmeddelandet på en punkt. Bokslutskommuniké Årsredovisning Nyttjanderättstillgångar MEUR 130,5 MEUR 117,2 Summa tillgångar MEUR 743,2 MEUR 729,9 Skillnaden består i tillägget av ett tyskt hyreskontrakt förlängt från 2024-01-01, undertecknat 2023. Inga effekter i resultaträkningen för 2023. Bilagor feni-2023-12-31-enAnnual_Report_2023Årsredovisning_2023CSR_2023

Fenix Outdoor: Fenix Outdoor International AG Annual and CSR report 202328.3.2024 15:00:00 CET | Press release

Zug 2024-03-28 Pressrelease - Annual and CSR report 2023 Attached Annual and CSR report 2023. The annual report differs from the Q4 press release in one position. Q4 Press release Annual Report Right of Use asset MEUR 130.5 MEUR 117,2 Total Asset MEUR 743.2 MEUR 729.9 The reason for the difference is the addition of a German lease contract prolonged from 2024-01-01, signed in 2023. No effects in Income statement for 2023. Attachments feni-2023-12-31-enAnnual_Report_2023Årsredovisning_2023CSR_2023

eQ Plc Managers' Transactions – Staffan Jåfs28.3.2024 15:00:00 CET | Press release

eQ Plc Managers' Transactions 28 March 2024 at 4:00 p.m. Person subject to the notification requirement Name: Staffan Jåfs Position: Other senior manager Issuer: eQ Oyj LEI: 743700R4FA6AVH5J3D68 Notification type: INITIAL NOTIFICATION Reference number: 57077/4/4 ____________________________________________ Transaction date: 2024-03-26 Outside a trading venue Instrument type: SHARE ISIN: FI0009009617 Nature of transaction: SUBSCRIPTION (X) Linked to stock option programme Transaction details (1): Volume: 65000 Unit price: 3.62 EUR Aggregated transactions (1): Volume: 65000 Volume weighted average price: 3.62 EUR eQ Plc Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733 Distribution: Nasdaq Helsinki, www.eQ.fi eQ Group is a Finnish group of companies specialising in asset management and corporate finance business. eQ Asset Management offers a wide range of asset management services (including private equity funds and real estate asset management) for institu

Exterro Hires Rick Valentine as New Chief Customer Officer28.3.2024 14:00:00 CET | Press release

Seasoned executive will focus on ensuring Exterro customers maximize the value of their investment PORTLAND, Ore., March 28, 2024 (GLOBE NEWSWIRE) -- Exterro, the leading provider of data risk management software solutions, today announced the appointment of Rick Valentine, an expert in delivering world-class customer experiences at global organizations, as its new chief customer officer. The appointment reflects Exterro’s long-term commitment to delivering an outstanding experience and return on investment to all customers using its data risk management platform. Valentine will report directly to Exterro CEO Bobby Balachandran. Valentine brings more than three decades of leadership experience to the CCO position, most recently as chief customer officer at data management company Quantum. His prior executive experience encompasses both large public enterprises and high-growth startups in the high-tech space, including Silver Peak Systems/HPE, Veritas/Symantec, and Intuit. Valentine bri

Now Open for Nominations: The First Edition of the Stevie® Awards for Technology Excellence28.3.2024 14:00:00 CET | Press release

The newest edition of the world’s premier business awards will celebrate technology-related achievements worldwide FAIRFAX, Va., March 28, 2024 (GLOBE NEWSWIRE) -- The Stevie® Awards, organizers of the world’s premier business awards, have opened a ninth international competition: the Stevie® Awards for Technology Excellence. This new Stevie Awards program celebrates the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors. Individuals and organizations worldwide are eligible to enter – public and private, for-profit and non-profit, large and small. The program will recognize the world’s best technology professionals, organizations, achievements, products, and services since the beginning of 2022. The early-bird entry deadline, with reduced entry fees, is May 2. The entry deadline is May 30, but late entries will be accepted through June 28 with payment of a late fee. Entry details are available at www.StevieAw

HiddenA line styled icon from Orion Icon Library.Eye